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ABSTRACT
Objectives: Rescreen a large community cohort to
examine the progression to heart failure over time and
the role of natriuretic peptide testing in screening.
Design: Observational longitudinal cohort study.
Setting: 16 socioeconomically diverse practices in
central England.
Participants: Participants from the original
Echocardiographic Heart of England Screening
(ECHOES) study were invited to attend for rescreening.
Outcome measures: Prevalence of heart failure at
rescreening overall and for each original ECHOES
subgroup. Test performance of N Terminal pro-B-type
Natriuretic Peptide (NT-proBNP) levels at different
thresholds for screening.
Results: 1618 of 3408 participants underwent
screening which represented 47% of survivors and
26% of the original ECHOES cohort. A total of 176
(11%, 95% CI 9.4% to 12.5%) participants were
classified as having heart failure at rescreening; 103
had heart failure with reduced ejection fraction (HFREF)
and 73 had heart failure with preserved ejection
fraction (HFPEF). Sixty-eight out of 1232 (5.5%, 95%
CI 4.3% to 6.9%) participants who were recruited from
the general population over the age of 45 and did not
have heart failure in the original study, had heart failure
on rescreening. An NT-proBNP cut-off of 400 pg/mL
had sensitivity for a diagnosis of heart failure of 79.5%
(95% CI 72.4% to 85.5%) and specificity of 87%
(95% CI 85.1% to 88.8%).
Conclusions: Rescreening identified new cases of
HFREF and HFPEF. Progression to heart failure poses
a significant threat over time. The natriuretic peptide
cut-off level for ruling out heart failure must be low
enough to ensure cases are not missed at screening.
INTRODUCTION
Chronic heart failure is a clinical syndrome,
which occurs following signiﬁcant pathological
insult to the heart acutely or over a period of
time, and is associated with poor outcomes for
patients.1–3 In many cases, symptoms are insidi-
ous in onset and overlap with other conditions
meaning diagnosis can be difﬁcult.4 Timely
diagnosis is important since early intervention
can improve quality of life and survival rates.5
Epidemiological studies have focused on the
point prevalence of heart failure, which is
around 1–1.5% in the general population
rising with age to 10% of those over 75 years in
some studies,6 and particularly on the develop-
ment of heart failure following myocardial
infarction7; yet the progression to heart failure
in the general community population over
time is less well understood. Natriuretic pep-
tides are increasingly being used to determine
whether heart failure is more or less likely in
patients presenting with symptoms in clinical
practice. An N-Terminal-pro-B-type Natriuretic
Peptide (NT-proBNP) level less than 400 pg/
mL is the current threshold suggested by the
National Institute for Health and Care
Excellence in England for ruling out a diagno-
sis of heart failure.8 The European Society of
Cardiology recommend a lower cut-off with
Strengths and limitations of this study
▪ The study represents a rescreen of one of the
largest well-phenotyped cohorts screened for
heart failure in the world.
▪ Contemporary echocardiographic equipment and
techniques were used to diagnose heart failure.
▪ The high interval death and non-responder rates
limit the generalisability to participants surviving
10 years and willing to be rescreened.
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NT-proBNP level less than 125 pg/mL used to exclude
heart failure.5 The role of natriuretic peptide testing, and
appropriate cut-off levels, in screening has not been fully
established.
The Echocardiographic Heart of England Screening
(ECHOES) study was one of the largest community
heart failure screening studies in the world and identi-
ﬁed an overall prevalence of 2.3% in participants over
the age of 45 years in the general population.9 The
ECHOES-extension (ECHOES-X) study started 10 years
after the ECHOES study completed, to rescreen partici-
pants from the original cohort. The aim of the
ECHOES-X study was to determine the progression to
heart failure over time and to examine the role of natri-
uretic peptide testing in screening for heart failure in a
community population.
METHODS
The ECHOES-X study was an observational longitudinal
study with the aim of rescreening all surviving partici-
pants from the original ECHOES study to determine the
prevalence of heart failure and performance of
NT-proBNP testing at rescreen.
Original ECHOES study population
Participants in ECHOES-X were derived from the ori-
ginal ECHOES study cohort, which screened 6162 parti-
cipants from 16 socioeconomically diverse general
practices in central England between March 1995 and
February 1999.9 A full clinical assessment, combined
with echocardiography and ECG, was used to determine
the presence of heart failure or left ventricular systolic
dysfunction (LVSD; deﬁned as an ejection fraction less
than 40%). The European Society of Cardiology criteria
published in 1995 were used to determine a diagnosis of
heart failure.10 A subgroup of the study population also
had a natriuretic peptide level recorded. The ECHOES
study comprised four subgroups: general population
over age 45; participants with risk factors (hypertension,
history of myocardial infarction, angina and diabetes);
participants with a prior diagnosis of heart failure; and a
group prescribed diuretics. The 5 and 10 year survival
rates of the overall cohort and subgroups have been
published.11
ECHOES-X study population
All participants involved in the original ECHOES study
had their medical record ‘ﬂagged’, to enable the Ofﬁce
for National Statistics to report all deaths to the study
team. A total of 2754 participants of the original
ECHOES study had died prior to recruitment to the
ECHOES-X study. All 3408 surviving participants were
eligible to take part in the ECHOES-X study. All 16 prac-
tices included in the original ECHOES study agreed to
participate in the follow-up. All eligible patients were
sent written information about the study prior to
screening. Those willing to take part provided written
informed consent prior to assessment.
Screening assessment
All participants underwent clinical assessment by a
general practitioner with an interest in cardiovascular
disease, or a trained research nurse. ECG and echocardi-
ography were carried out by an echocardiographer
accredited by the British Society of Echocardiography. A
full echocardiographic assessment was performed using
a GE Vivid-I machine with spectral Tissue Doppler to
assess diastolic function via measurement of E:e0 ratio.
In addition, participants had a blood test to measure
NT-proBNP levels using a Roche near patient testing
device. All participants were also invited to complete a
quality-of-life questionnaire. Data collection was carried
out between October 2008 and June 2011.
Heart failure diagnostic criteria
The revised 2012 European Society of Cardiology (ESC)
chronic heart failure guideline was used to provide a con-
temporary deﬁnition of heart failure.5 Participants with
symptoms and an ejection fraction of 50% or less were
categorised as heart failure with reduced ejection fraction
(HFREF) and those with symptoms, ejection fraction
above 50% and evidence of diastolic dysfunction, signiﬁ-
cant valve disease or arrhythmia were categorised as heart
failure with preserved ejection fraction (HFPEF) using a
diagnostic algorithm. Of note, natriuretic peptide level
was not included in the diagnostic algorithm to allow sub-
sequent calculation of test performance. Where the diag-
nosis was in doubt, cases were reviewed by a panel of
Table 1 ECHOES-X criteria for objective evidence of
heart failure
Abnormality Criteria
Type of
heart
failure
Left ventricular
systolic dysfunction
Ejection fraction 40% HFREF
Borderline left
ventricular systolic
dysfunction
Ejection fraction
41–50%
HFREF
Diastolic
dysfunction
Diastolic dysfunction
defined as E:e0 >13 or
E:e0 8–13 with LV
hypertrophy (IVS
>1.2 cm) or LA
enlargement (>4 cm
(males); >3.8 cm
(females))
HFPEF
Significant valvular
disease
Moderate to severe
(grade 2–3)
HFPEF
Atrial fibrillation Diagnosed on ECG HFPEF
HFPEF, heart failure with preserved ejection fraction; HFREF,
heart failure with reduced ejection fraction; IVS, interventricular
septum; LA, left atrium.
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three clinicians with expertise in heart failure. The cri-
teria for objective evidence, and corresponding type of
heart failure, are shown in table 1.
Statistical methods
The overall prevalence rate of heart failure, subdivided
into HFREF and HFPEF, was calculated for the
ECHOES-X cohort. Prevalence of objective abnormalities
for participants with and without heart failure was also
calculated. The prevalence of heart failure by original
diagnostic group was also determined. The general popu-
lation subgroup was considered alone to determine the
progress to new heart failure at rescreening. Finally, the
median values of NT-proBNP were calculated for partici-
pants with and without heart failure, and performance
characteristics for diagnosing heart failure, including sen-
sitivity, speciﬁcity, and positive and negative predictive
values, were calculated for a NT-proBNP threshold of 125
and 400 pg/mL. No data were available for those who did
not attend for rescreening. CIs were calculated using the
binomial exact method. Statistical analyses were under-
taken using SAS V.9.2 and Stata V.12.1.
RESULTS
A total of 1618 of 3408 participants who were still alive
at the start of the study underwent screening which
represented 47% of survivors and 26% of the original
ECHOES cohort. Figure 1 provides a summary showing
ﬂow and number of participants in the ECHOES and
ECHOES-X studies.
The baseline characteristics of the ECHOES and
ECHOES-X cohort are given in table 2. Average age was
64 years in ECHOES and 71 years in ECHOES-X with an
equal gender mix in both studies. The mean time
between screenings was 13.4 years (SD 1.3, range 10.2–
15.5 years).
Figure 1 Summary of participant numbers in ECHOES and ECHOES-X studies.
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The number of participants who were rescreened did
not respond or had died are shown in table 3, grouped
according to their original ECHOES recruitment sub-
group. Eighty per cent of those in the ‘previous label of
heart failure’ group in the original study had died.
Those in the ‘on diuretics’ group also had a higher pro-
portion of deaths (59%) than the general population
group (36%).
Prevalence of heart failure in ECHOES-X
A total of 176 (11%) participants from all four original
recruitment groups were classiﬁed as having heart failure
at rescreening; 103 (58.5%) participants had symptoms
and an ejection fraction less than 50% and could there-
fore be classiﬁed as HFREF. The remaining 73 (41.4%)
participants with heart failure had an ejection fraction
above 50% with evidence of diastolic dysfunction, atrial
ﬁbrillation or signiﬁcant valve disease and were classiﬁed
as HFPEF. Eighty four participants of 176 (47.7%) with
heart failure had more than one objective abnormality.
Signiﬁcant valve disease or atrial ﬁbrillation was present
in over one-third of heart failure cases and diastolic dys-
function was found in over 30%. In the general popula-
tion group alone, there were 73 cases of heart failure out
of 1242 participants rescreened giving a prevalence of
5.9% (95% CI 4.6% to 7.3%) in this group.
A total of 1442 participants did not have a diagnosis of
heart failure according to the ESC deﬁnition but a sig-
niﬁcant number of this group had one or more object-
ive abnormality of cardiac function. One hundred and
ﬁve (7%) participants without heart failure had signiﬁ-
cant valvular disease and 37 (2.6%) had an ejection frac-
tion less than 50%. Diastolic dysfunction was present in
30 (2%) of the no heart failure group. Sixty two (35%)
of participants in the heart failure group had atrial ﬁbril-
lation compared to 36 out of 1442 (2.5%) in the non-
heart failure group. Overall the prevalence of atrial ﬁb-
rillation in the ECHOES-X cohort was 6%.
Outcome of participants from the original ECHOES cohort
Participants in the original ECHOES study were cate-
gorised into four diagnostic groups following screening;
no heart failure and no LVSD, heart failure and no
LVSD, no heart failure and LVSD and heart failure and
LVSD. Table 4 shows the ECHOES-X outcome for each
group. One hundred and eighty-four out of 219 (84%)
participants with heart failure and LVSD and 194 partici-
pants out of 230 (84%) with heart failure and no LVSD
had died. Eighty out of 109 (73%) participants with no
heart failure and LVSD had also died. The largest group
was participants with no heart failure and no LVSD from
the original ECHOES study and of these, 144 out of
1579 (9.1%) participants rescreened had a label of heart
failure.
Progression to heart failure
When the original ECHOES study was reported, 5604
participants were assessed and found not to have heart
failure or LVSD as shown in table 4. However, ECHOES-X
included some participants particularly at high risk of
heart failure, so to have a true baseline group to calculate
heart failure progression, the general population group
should be considered alone (table 5). Data collection for
the original ECHOES study took place between 1995 and
1999 and for the ECHOES-X study between 2008 and
2011. On completion of the ECHOES-X study, of the
3834 participants from the general population cohort in
the no heart failure, no LVSD group in the original study,
1323 participants had died, 1279 did not respond and
1232 had attended for rescreening. Of the 1232 partici-
pants rescreened, 68 (5.5%, 95% CI 4.3% to 6.9%) were
found to have heart failure.
A breakdown of progression to heart failure (including
cause) according to original ECHOES recruitment sub-
group is shown in table 6. Of those recruited to the original
Table 2 Baseline characteristics of ECHOES and
ECHOES-X cohort
Characteristic ECHOES (%) ECHOES-X (%)
Age (years) 64 71
Gender male 3083 (50) 803 (49.7)
Ethnicity
Caucasian 5972 (96.9) 1579 (97.8)
Asian 34 (0.5) 6 (0.5)
Chinese 3 (0.1) 1 (0.1)
Black 126 (2.1) 23 (1.5)
Other 13 (0.2) 6 (0.4)
Not known 14 (0.2) 1 (<0.1)
Table 3 Number of participants in ECHOES-X from ECHOES cohort by original recruitment group
Original ECHOES cohort
Original
sample size
Number
rescreened
Number of
non-responders
Number
died
General population aged 45+ 3960 1242 (31%) 1299 (33%) 1419 (36%)
Previous label HF 782 59 (8%) 97 (12%) 626 (80%)
On diuretics 928 162 (17%) 222 (24%) 544 (59%)
High risk 1062 214 (20%) 297 (28%) 551 (52%)
Total 6162* 1618* (26%) 1790* (29%) 2754* (44%)
*Some participants are in more than one cohort.
HF, heart failure.
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study from the general population over the age of 45, 73
out of 1242 (5.9%, 95% CI 4.6% to 7.3%) rescreened parti-
cipants had a diagnosis of heart failure in the ECHOES-X
study. Forty seven out of 214 (22%, 85% CI 16.6% to
28.1%) participants with risk factors at the time of the ori-
ginal study (hypertension, diabetes, angina or history of
myocardial infarction) had heart failure at rescreening.
Heart failure was more common still in patients on diure-
tics or with a previous label of heart failure.
NT-proBNP levels in those with heart failure
All participants in ECHOES-X were invited to have a
blood test to assess NT-proBNP. Two attempts were made
to take blood in those who provided consent.
NT-proBNP level was available for 1511 (93%) partici-
pants. The median NT-proBNP level was 772 pg/mL
(IQR 454–1338 pg/mL) in those with heart failure and
135 pg/mL (IQR 72–255 pg/mL) in those without heart
failure. Thirty three of 176 (18.8%) participants with
heart failure had an NT-proBNP level less than 400 pg/
mL, the current threshold suggested by the National
Institute for Health and Care Excellence in England for
ruling out a diagnosis of heart failure. A cut-off of
400 pg/mL had sensitivity for a diagnosis of heart failure
of 79.5% (95% CI 72.4% to 85.5%), speciﬁcity of 87%
(95% CI 85.1% to 88.8%), positive predictive value of
42.2% (95% CI 36.6% to 48.0%) and negative predictive
value of 97.3% (95% CI 96.2% to 98.1%). A lower
cut-off of NT-proBNP less than 125 pg/mL has a sensitiv-
ity of 96.3% (95% CI 92.1% to 98.6%), speciﬁcity of
46.8% (95% CI 44.1% to 49.5%), positive predictive
value of 17.8% (95% CI 15.3% to 20.5%) and negative
predictive value of 99.1% (95% CI 98.0% to 99.7%).
DISCUSSION
Summary of findings
Most patients with heart failure and/or LVSD in the ori-
ginal ECHOES cohort had died in the decade before
rescreening started. At rescreening, those with cardiovas-
cular risk factors in the original cohort were more likely to
have heart failure on rescreening than those from the
general population group. HFPEF was not recorded at the
time of the original ECHOES study but accounted for
47% of heart failure cases in the ECHOES-X cohort. This
would have been partially captured in the heart failure, no
LVSD group of ECHOES. Multiple objective abnormalities
were found in patients with heart failure in ECHOES-X
suggesting a complex and multifactorial disease.
NT-proBNP levels were generally higher in patients with
heart failure, yet almost 20% had levels below a 400 pg/
mL cut-off for heart failure, meaning this cut-off may be
inappropriate for screening in a community setting.
Strengths and weaknesses of the study
The ECHOES study provided one of the largest commu-
nity heart failure screening cohorts in the world. The
ECHOES-X study followed up those still alive with a
comprehensive clinical assessment to establish or rule
out a diagnosis of heart failure. Progression to heart
failure according to baseline group and the prevalence
of HFREF versus HFPEF within the cohort are important
epidemiological ﬁndings which advance our understand-
ing of heart failure in community populations. The pres-
ence of multiple echocardiographic abnormalities and
the performance of natriuretic peptide testing are
important considerations for future screening for heart
failure in community settings.
Table 4 Outcome for ECHOES cohort by original diagnostic group
Original ECHOES
diagnostic group
Original
sample size Died
HF on
rescreen
No HF
on rescreen Non-responders
No HF and no LVSD 5604 2296 144 1435 1729
HF and no LVSD 230 194 12 1 23
No HF and LVSD 109 80 7 6 16
HF and LVSD 219 184 13 0 22
Total 6162 2754 176 1442 1790
HF, heart failure, LVSD, left ventricular systolic dysfunction.
Table 5 Outcome for general population ECHOES cohort by original diagnostic group
Original ECHOES
diagnostic group
Original
sample size Died
HF on
rescreen
No HF
on rescreen Non-responders
No HF and no LVSD 3834 1323 68 1164 1279
HF and no LVSD 54 43 2 1 8
No HF and LVSD 34 19 2 4 9
HF and LVSD 38 34 1 0 3
Total 3960 1419 73 1169 1299
HF, heart failure; LVSD, left ventricular systolic dysfunction.
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Diagnosis was determined according to the latest guid-
ance from the European Society of Cardiology, which
was agreed by a large expert panel of specialists in the
ﬁeld.4 However, the deﬁnition requires symptoms to be
present for a diagnosis of heart failure to be made, yet
patients on known effective treatments such as ACE inhi-
bitors, β-blockers or diuretics may have been rendered
asymptomatic by therapy. The estimate of heart failure
prevalence is therefore likely to be a conservative one in
the ECHOES and ECHOES-X studies.
The ECHOES and ECHOES-X studies were carried
out a decade apart during which time there are likely to
have been incident cases of heart failure patients who
subsequently died. A further limitation of the study is
that half of all eligible participants did not attend for
rescreening. These results, therefore, give an estimate
only for those who survived and were rescreened.
Screening in itself requires high attendance rates to
confer beneﬁt and this is a consideration for any future
screening programme.
A range of ethnic groups and social classes were repre-
sented in the ECHOES cohort to ensure the study was
generalisable to community populations in Europe.9
The proportion of white Caucasians in ECHOES-X was
greater than the UK average and black Africans were
under-represented; however, the E-ECHOES study,
which speciﬁcally included South Asian and Black parti-
cipants, found rates of heart failure which were similar
to the white population.12
The original ECHOES study required a reduced ejec-
tion fraction or other structural or functional abnormal-
ity, such as valve disease or arrhythmia, for a diagnosis of
heart failure and did not attempt to phenotype
HFPEF.13 Participants with heart failure due to atrial ﬁb-
rillation may have partly captured the HFPEF group, but
it is likely that the original ECHOES study under-
reported the incidence of heart failure overall according
to contemporary deﬁnitions.7 Echocardiography tech-
nology has also improved signiﬁcantly since the original
study; for example, tissue Doppler, which is used to diag-
nose diastolic dysfunction, was not available in 1995
when the original ECHOES study began.
Comparison with existing literature
There are several registries which document the
characteristics of patients admitted to hospital with heart
failure.14 Community-based studies, such as the
Framingham and Olmsted County studies in the USA or
the Rotterdam study in the Netherlands, have followed
up patients over a number of decades to describe the
epidemiology of cardiovascular diseases, including heart
failure.15–17 However, the ECHOES-X study represents
the ﬁrst follow-up study of a large UK cohort previously
screened for heart failure. In particular, patients selected
from the general population and found not to have
heart failure a decade ago were rescreened to ﬁnd who
had developed the disease.
At the time of the original ECHOES study, HFPEF was
not recorded as a separate diagnostic category,18 but the
follow-up study used the latest echocardiographic deﬁn-
ition to identify participants with HFPEF. In ECHOES-X,
73 of a total of 176 (41%) participants with heart failure
were classiﬁed as HFPEF. Pooled estimates from inter-
national community-based studies found an average
HFPEF prevalence of 54% (range 40–71%) among
those with heart failure.19 The presence of multiple
echocardiographic abnormalities was also found in
ECHOES-X and has been shown in previous screening
studies to be associated with a signiﬁcant increase in all-
cause mortality.20
HFREF and HFPEF were more common in partici-
pants with cardiovascular risk factors at baseline, com-
pared with the general population, which is consistent
with recent ﬁndings from Framingham.12 However, the
onset of heart failure timing in Framingham was deter-
mined according to outpatient and hospital records. In
ECHOES-X, patients were fully screened, including
echocardiography and NT-proBNP testing, to actively
seek out new heart failure. The ECHOES-X results there-
fore represent ﬁndings from an actively screened com-
munity population.
The high prevalence of AF and other cardiac abnor-
malities in patients from high-risk groups in the
ECHOES cohort has been previously reported.21 The
ECHOES-X data conﬁrm a high rate of AF and other
echocardiographic abnormalities in the heart failure
group. The role of NT-proBNP in predicting prognosis
of patients with heart failure has also been explored in
ECHOES, but only 10% of the original cohort had a
recorded natriuretic peptide level.22 A subsequent
follow-up of the ECHOES-X cohort (with >90% having a
baseline NT-proBNP level recorded) to further assess
Table 6 Progression to heart failure according to original ECHOES recruitment subgroup
Original ECHOES cohort
Original
sample size
Number
rescreened
Heart failure (% of rescreened group)
HFREF HFPEF Total
Generation poppulation aged 45+ 3960 1242 39 (3.1%) 34 (2.7%) 73 (5.9%)
Previous label HF 782 59 24 (40.7%) 11 (18.6%) 35 (59.3%)
On diuretics 928 162 24 (14.8%) 17 (10.5%) 41 (25.3%)
Risk factors 1062 214 28 (13.1%) 19 (8.9%) 47 (22.0%)
Total 6162 1618 103 (6.4%) 73 (4.5%) 176 (10.9%)
Percentages are proportion of total number in subgroup.
HF, heart failure; HFPEF, heart failure with preserved ejection; HFREF, heart failure with reduced ejection fraction; fraction.
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the value of NT-proBNP in predicting prognosis may be
warranted.
Further research and recommendations
Screening highlighted a signiﬁcant number of patients
with heart failure in a population aged 55 and over, and
may provide a window of opportunity to intervene early
and prevent heart failure progression, ultimately improv-
ing quality of life and survival. Screening of the high-risk
groups, where prevalence of heart failure is highest,
would seem most effective and indeed data from the
high-risk groups in the original ECHOES study helped
inform the UK Cardiovascular Disease National Service
Framework23 and other guidelines,24 recommending
that echocardiography be undertaken in all patients fol-
lowing myocardial infarction, but how frequently
patients should be rescreened is still unknown.
Other structural and functional abnormalities can also
be discovered in asymptomatic patients, which may
provide further opportunities to provide timely treat-
ment. For example, operating on patients with signiﬁ-
cant valvular disease who are well at the time of surgery
substantially reduces their perioperative risk.25 Further
investigation into the clinical and cost effectiveness of
optimal intervention for LVSD is also warranted. The
level of natriuretic peptides currently used to rule out
heart failure may be too high for a screened population.
Nearly 20% of participants in the heart failure group
had an NT-proBNP level less than the current threshold
in some national guidelines.8
Conclusion
Progression to heart failure is more common in high
risk groups but even in the general population is signiﬁ-
cant over time and screening provides an opportunity to
identify new cases. The natriuretic peptide cut-off level
for ruling out heart failure must be low enough to
ensure cases are not missed in a screened population.
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